Article

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine and Risperidone in Alzheimer’s Disease: A Real□World Cohort Study with Treatment Effect Heterogeneity Analysis

2025-11-15

Abstract excerpt

<h4>Background</h4> Second-generation antipsychotics (SGAs) are frequently used off-label to manage behavioral symptoms in Alzheimer’s disease (AD), despite ongoing concerns about their safety. Comparative evidence on mortality risk across specific SGAs remains limited. <h4>Objective</h4> To compare all-cause mortality among AD patients treated with commonly prescribed SGAs and to explore treatment effect hetero...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3cd331c7-60cb-5242-87a9-fb9a6eace7f0
DOI: 10.1101/2025.11.13.25340096

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine and Risperidone in Alzheimer’s Disease: A Real□World Cohort Study with Treatment Effect Heterogeneity AnalysisDOI 10.1101/2025.11.13.25340096Read

Medication-Wide Association Study of Alzheimer’s Disease and Related Dementias: Identifying Drug Candidates from Electronic Health Records through Explainable AISemantic proximity Read

The heterogeneous treatment effects of statins on dementia: a target trial emulation with causal machine learning using integrated genetic and real-world data.Semantic proximity Read

The risk of Alzheimer's disease and cognitive impairment characteristics in eight mental disorders: A UK Biobank observational study and Mendelian randomization analysisSemantic proximity Read

Development and validation of a personalised antipsychotic selection tool for first-line treatment in severe mental illnessSemantic proximity Read

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's DiseaseSemantic proximity Read

Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identificationSemantic proximity Read

Medication Exposure and Neurodegenerative Disease Risk Across National BiobanksSemantic proximity Read

Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learningSemantic proximity Read

Identifying incident dementia by applying machine learning to a very large administrative claims datasetSemantic proximity Read

Effect of initiating an ARB- versus ACEI-based regimen on dementia risk, a target trial emulation of 2.5 million US VeteransSemantic proximity Read

Distinct medical and substance use histories associate with cognitive decline in Alzheimer’s DiseaseSemantic proximity Read

Causal relationship of COVID-19 on Alzheimer’s disease: an updated Mendelian randomization studySemantic proximity Read